Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 216Stomach Neoplasms 166Rectal Neoplasms 146Pancreatic Neoplasms 81Colonic Neoplasms 77Neoplasm Metastasis 67Esophageal Neoplasms 55Neoplasms 31Adenocarcinoma Of Esophagus 29Cholangiocarcinoma 28Carcinoma, Hepatocellular 26Adenocarcinoma 26Biliary Tract Neoplasms 23Lymphoma, Large B-Cell, Diffuse 19Recurrence 17Carcinoma, Non-Small-Cell Lung 16Gallbladder Neoplasms 14Breast Neoplasms 14Head and Neck Neoplasms 11Locally Advanced Rectal Cancer 10Liver Neoplasms 10Gastrointestinal Neoplasms 10Esophageal Squamous Cell Carcinoma 9Peritoneal Neoplasms 8Ovarian Neoplasms 8Colorectal Cancer Metastatic 7Bile Duct Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Extranodal NK-T-Cell 5

Interventions

Bevacizumab 2trifluridine tipiracil drug combination 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × mCRC × Oxaliplatin × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡